Have a feature idea you'd love to see implemented? Let us know!

GRCE Grace Therapeutics Inc.

Price (delayed)

$4.34

Market cap

$44.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.01

Enterprise value

$28.85M

Highlights
The debt has shrunk by 100% YoY
The EPS has surged by 81% year-on-year and by 11% since the previous quarter
Grace Therapeutics's quick ratio has shrunk by 71% YoY and by 23% QoQ
The company's equity fell by 16% YoY and by 5% QoQ

Key stats

What are the main financial stats of GRCE
Market
Shares outstanding
10.14M
Market cap
$44.01M
Enterprise value
$28.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$15.08M
EBITDA
-$15.07M
Free cash flow
-$11.84M
Per share
EPS
-$1.01
Free cash flow per share
-$1.03
Book value per share
$5.54
Revenue per share
$0
TBVPS
$1.4
Balance sheet
Total assets
$65.35M
Total liabilities
$9.22M
Debt
$0
Equity
$56.13M
Working capital
$13.39M
Liquidity
Debt to equity
0
Current ratio
6.01
Quick ratio
5.83
Net debt/EBITDA
1.01
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-16.3%
Return on equity
-19.2%
Return on invested capital
-2,246.4%
Return on capital employed
-24.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GRCE stock price

How has the Grace Therapeutics stock price performed over time
Intraday
6.37%
1 week
28.78%
1 month
42.76%
1 year
90.35%
YTD
50.17%
QTD
44.67%

Financial performance

How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.1M
Net income
-$11.61M
Gross margin
N/A
Net margin
N/A
Grace Therapeutics's net income has soared by 71% YoY
GRCE's operating income has soared by 67% year-on-year but it is down by 20% since the previous quarter

Growth

What is Grace Therapeutics's growth rate over time

Valuation

What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 81% year-on-year and by 11% since the previous quarter
The stock's P/B is 56% above its last 4 quarters average of 0.5 but 22% below its 5-year quarterly average of 1.0
The company's equity fell by 16% YoY and by 5% QoQ

Efficiency

How efficient is Grace Therapeutics business performance
Grace Therapeutics's ROIC has plunged by 95% from the previous quarter but it has increased by 47% YoY
The ROA has soared by 65% YoY but it has contracted by 6% from the previous quarter
The ROE has soared by 65% YoY but it has contracted by 6% from the previous quarter

Dividends

What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRCE.

Financial health

How did Grace Therapeutics financials performed over time
Grace Therapeutics's quick ratio has shrunk by 71% YoY and by 23% QoQ
The company's current ratio has shrunk by 71% YoY and by 24% QoQ
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
The company's equity fell by 16% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.